SCHEMBL5350192

SCHEMBL5350192

O=Cc1ccccc1C(=O)N[S]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
BLM P54132 1/20 0.46
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
SRC P12931 1/20 0.39
ALDH1A1 P00352 5/20 0.39
TSHR P16473 1/20 0.39
HPGD P15428 3/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3419592 0.84 MEN1 (0.46) MEN1KMT2ATDP1LMNATHRB
SCHEMBL7542943 0.82 GAA (0.55) MEN1KMT2ATDP1LMNATHRB
SCHEMBL1932685 0.82 MEN1 (0.48) MEN1KMT2ATDP1LMNATHRB
SCHEMBL6328702 0.80 CTSD (0.50) MEN1KMT2ATDP1LMNATHRB
SCHEMBL728983 0.80 GAA (0.55) MEN1KMT2ATDP1LMNATHRB
SCHEMBL7199863 0.80 MEN1 (0.46) MEN1KMT2ATDP1LMNATHRB
SCHEMBL5350946 0.78 TDP1 (0.44) MEN1KMT2ATDP1LMNATHRB
SCHEMBL8470340 0.78 SRC (0.46) MEN1KMT2ATDP1LMNATHRB
SCHEMBL9825116 0.78 CA1 (0.62) MEN1KMT2ATDP1LMNATHRB
SCHEMBL5355977 0.77 MEN1 (0.43) MEN1KMT2ATDP1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 MEN1 3783/4885KMT2A 649/4885TDP1 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.